BR112018074456A2 - anticorpos que se ligam especificamente aos epítopos do zika vírus e usos dos mesmos - Google Patents

anticorpos que se ligam especificamente aos epítopos do zika vírus e usos dos mesmos

Info

Publication number
BR112018074456A2
BR112018074456A2 BR112018074456-5A BR112018074456A BR112018074456A2 BR 112018074456 A2 BR112018074456 A2 BR 112018074456A2 BR 112018074456 A BR112018074456 A BR 112018074456A BR 112018074456 A2 BR112018074456 A2 BR 112018074456A2
Authority
BR
Brazil
Prior art keywords
antibodies
specifically bind
zika virus
relates
virus epitopes
Prior art date
Application number
BR112018074456-5A
Other languages
English (en)
Portuguese (pt)
Inventor
Corti Davide
Original Assignee
Humabs Biomed Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Humabs Biomed Sa filed Critical Humabs Biomed Sa
Publication of BR112018074456A2 publication Critical patent/BR112018074456A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C07K16/116—Togaviridae (F); Matonaviridae (F); Flaviviridae (F)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/08—RNA viruses
    • G01N2333/18—Togaviridae; Flaviviridae
    • G01N2333/183—Flaviviridae, e.g. pestivirus, mucosal disease virus, bovine viral diarrhoea virus, classical swine fever virus (hog cholera virus) or border disease virus
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2469/00—Immunoassays for the detection of microorganisms
    • G01N2469/10—Detection of antigens from microorganism in sample from host
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
BR112018074456-5A 2016-07-13 2017-07-12 anticorpos que se ligam especificamente aos epítopos do zika vírus e usos dos mesmos BR112018074456A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
PCT/EP2016/066684 WO2018010789A1 (en) 2016-07-13 2016-07-13 Novel antibodies specifically binding to zika virus epitopes and uses thereof
EPPCT/EP2016/066684 2016-07-13
PCT/EP2017/067581 WO2018011283A1 (en) 2016-07-13 2017-07-12 Novel antibodies specifically binding to zika virus epitopes and uses thereof

Publications (1)

Publication Number Publication Date
BR112018074456A2 true BR112018074456A2 (pt) 2019-03-19

Family

ID=56413654

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112018074456-5A BR112018074456A2 (pt) 2016-07-13 2017-07-12 anticorpos que se ligam especificamente aos epítopos do zika vírus e usos dos mesmos

Country Status (31)

Country Link
US (3) US11117954B2 (cg-RX-API-DMAC10.html)
EP (2) EP3484915B1 (cg-RX-API-DMAC10.html)
JP (2) JP7252888B2 (cg-RX-API-DMAC10.html)
KR (1) KR102595764B1 (cg-RX-API-DMAC10.html)
CN (2) CN116199775A (cg-RX-API-DMAC10.html)
AU (1) AU2017297757B2 (cg-RX-API-DMAC10.html)
BR (1) BR112018074456A2 (cg-RX-API-DMAC10.html)
CA (1) CA3024374A1 (cg-RX-API-DMAC10.html)
CL (2) CL2019000067A1 (cg-RX-API-DMAC10.html)
CO (1) CO2019001111A2 (cg-RX-API-DMAC10.html)
CR (1) CR20190066A (cg-RX-API-DMAC10.html)
DK (1) DK3484915T5 (cg-RX-API-DMAC10.html)
DO (2) DOP2019000006A (cg-RX-API-DMAC10.html)
EA (1) EA201990243A1 (cg-RX-API-DMAC10.html)
EC (1) ECSP19009170A (cg-RX-API-DMAC10.html)
ES (1) ES2959883T3 (cg-RX-API-DMAC10.html)
FI (1) FI3484915T3 (cg-RX-API-DMAC10.html)
HR (1) HRP20231196T1 (cg-RX-API-DMAC10.html)
HU (1) HUE063272T2 (cg-RX-API-DMAC10.html)
IL (1) IL262710B2 (cg-RX-API-DMAC10.html)
LT (1) LT3484915T (cg-RX-API-DMAC10.html)
MX (1) MX2019000526A (cg-RX-API-DMAC10.html)
MY (1) MY190553A (cg-RX-API-DMAC10.html)
PE (1) PE20190398A1 (cg-RX-API-DMAC10.html)
PH (1) PH12018502348B1 (cg-RX-API-DMAC10.html)
PL (1) PL3484915T3 (cg-RX-API-DMAC10.html)
SG (1) SG11201809879WA (cg-RX-API-DMAC10.html)
SI (1) SI3484915T1 (cg-RX-API-DMAC10.html)
UA (1) UA126381C2 (cg-RX-API-DMAC10.html)
WO (2) WO2018010789A1 (cg-RX-API-DMAC10.html)
ZA (1) ZA201807467B (cg-RX-API-DMAC10.html)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102405390B1 (ko) 2016-07-13 2022-06-03 에보닉 오퍼레이션스 게엠베하 용해된 지질을 함유하는 바이오매스로부터 지질을 분리하는 방법
CA3040189A1 (en) 2016-10-13 2018-04-19 Massachusetts Institute Of Technology Antibodies that bind zika virus envelope protein and uses thereof
WO2019042555A1 (en) 2017-08-31 2019-03-07 Humabs Biomed Sa MULTISPECIFIC ANTIBODIES SPECIFICALLY BINDING TO ZIKA VIRUS EPITOPES AND USES THEREOF
EP3527664A1 (en) 2018-02-15 2019-08-21 Evonik Degussa GmbH Method of isolating lipids from a lipids containing biomass
JP2019152666A (ja) * 2018-03-02 2019-09-12 富士レビオ株式会社 ジカウイルスを検出する方法及びキット
BR112020021928A2 (pt) 2018-04-24 2021-05-04 The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. anticorpos monoclonais potentes de neutralização cruzada e específicos do vírus da zika para vírus da zika e da dengue após infecção por zikv ou vacinação contra zikv
WO2019219443A1 (en) 2018-05-15 2019-11-21 Evonik Operations Gmbh Method of isolating lipids from a lipids containing biomass with aid of hydrophobic silica
WO2019219396A1 (en) 2018-05-15 2019-11-21 Evonik Operations Gmbh Method of isolating lipids from a lysed lipids containing biomass by emulsion inversion
WO2020061159A1 (en) * 2018-09-20 2020-03-26 Vanderbilt University Human antibodies to zika virus
WO2020078568A1 (en) 2018-10-19 2020-04-23 Humabs Biomed Sa Antibodies and methods for treatment of lyssavirus infection
WO2020092564A1 (en) * 2018-10-31 2020-05-07 Icahn School Of Medicine At Mount Sinai Human antibodies targeting zika virus ns1, ns1 polypeptides and uses thereof
JP7463366B2 (ja) * 2018-11-20 2024-04-08 タケダ ワクチン,インコーポレイテッド 新規の抗ジカウイルス抗体及びその使用
WO2020245663A1 (en) * 2019-06-01 2020-12-10 Institut Pasteur Nanobody-based ns1 assay for the specific diagnosis of acute zika virus infection
US12570725B2 (en) 2019-09-13 2026-03-10 Duke University ZIKA antibodies and their use
JP7725465B2 (ja) * 2019-11-07 2025-08-19 中国科学院微生物研究所 ジカ・デングワクチン及びその使用
WO2021101739A1 (en) * 2019-11-19 2021-05-27 Vanderbilt University Human antibodies that neutralize zika virus and methods of use therefor
CN111138534B (zh) * 2019-12-31 2021-09-28 武汉班科生物技术股份有限公司 寨卡病毒囊膜蛋白的鼠源单克隆抗体
CN111100201B (zh) * 2019-12-31 2021-09-28 武汉班科生物技术股份有限公司 针对寨卡病毒囊膜蛋白的鼠源单克隆抗体
JP7471555B2 (ja) * 2020-02-20 2024-04-22 国立感染症研究所長 フラビウイルス交差中和抗体及び医薬組成物
US20230324404A1 (en) 2020-05-20 2023-10-12 Takeda Vaccines, Inc. Method for detection of zika virus specific antibodies
WO2021236225A1 (en) 2020-05-20 2021-11-25 Takeda Vaccines, Inc. Method for detection of zika virus specific antibodies
JP2023527169A (ja) 2020-05-20 2023-06-27 タケダ ワクチン,インコーポレイテッド 抗原の効力を決定するための方法
CN115697392B (zh) * 2020-06-28 2026-03-13 神州细胞工程有限公司 一种降低病毒ade效应的方法
US20240180969A1 (en) * 2021-04-01 2024-06-06 A2 Biotherapeutics, Inc. Polypeptides targeting hla-a*11 and methods of use thereof
CN112921124B (zh) * 2021-04-08 2021-09-28 广东创晟控股集团有限公司 一种快速检测病毒的试剂盒
WO2024211789A1 (en) * 2023-04-07 2024-10-10 Fred Hutchinson Cancer Center Cross-flavivirus binding domains and uses thereof

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL154600B (nl) 1971-02-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen.
US3817837A (en) 1971-05-14 1974-06-18 Syva Corp Enzyme amplification assay
US3766162A (en) 1971-08-24 1973-10-16 Hoffmann La Roche Barbituric acid antigens and antibodies specific therefor
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4233402A (en) 1978-04-05 1980-11-11 Syva Company Reagents and method employing channeling
JPS5896026A (ja) 1981-10-30 1983-06-07 Nippon Chemiphar Co Ltd 新規ウロキナ−ゼ誘導体およびその製造法ならびにそれを含有する血栓溶解剤
US4609546A (en) 1982-06-24 1986-09-02 Japan Chemical Research Co., Ltd. Long-acting composition
US4766106A (en) 1985-06-26 1988-08-23 Cetus Corporation Solubilization of proteins for pharmaceutical compositions using polymer conjugation
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US4831175A (en) 1986-09-05 1989-05-16 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Backbone polysubstituted chelates for forming a metal chelate-protein conjugate
US5595721A (en) 1993-09-16 1997-01-21 Coulter Pharmaceutical, Inc. Radioimmunotherapy of lymphoma using anti-CD20
US20020102208A1 (en) 1999-03-01 2002-08-01 Paul Chinn Radiolabeling kit and binding assay
MY133346A (en) 1999-03-01 2007-11-30 Biogen Inc Kit for radiolabeling ligands with yttrium-90
US7785799B2 (en) 2002-08-16 2010-08-31 The Board Of Regents Of The University Of Texas System Compositions and methods related to flavivirus envelope protein domain III antigens
WO2004076677A2 (en) 2003-02-26 2004-09-10 Institute For Research In Biomedicine Monoclonal antibody production by ebv transformation of b cells
US7700097B2 (en) 2003-06-27 2010-04-20 Biogen Idec Ma Inc. Purification and preferential synthesis of binding molecules
MX2009012343A (es) 2007-05-14 2010-02-10 Biogen Idec Inc Regiones fc (sc fc) de cadena sencilla, polipeptidos de enlace que comprenden las mismas, y metodos relacionados con ello.
ES2525346T3 (es) 2008-10-22 2014-12-22 Institute For Research In Biomedicine Métodos para producir anticuerpos a partir de células plasmáticas
EP4292657A3 (en) * 2013-03-15 2024-03-20 Dana Farber Cancer Institute, Inc. Flavivirus neutralizing antibodies and methods of use thereof
BR112018068342A2 (pt) 2016-03-11 2019-01-15 Univ Johns Hopkins vacina de vírus zika vivo atenuado
WO2017181098A2 (en) * 2016-04-15 2017-10-19 Visterra, Inc. Antibody molecules to zika virus and uses thereof
TW201815821A (zh) 2016-07-18 2018-05-01 美商再生元醫藥公司 抗茲卡病毒抗體及使用方法
IL317854A (en) 2017-07-28 2025-02-01 Takeda Pharmaceuticals Co TYK2 inhibitors and their uses

Also Published As

Publication number Publication date
EP3484915B1 (en) 2023-08-16
DOP2019000006A (es) 2019-03-31
WO2018011283A1 (en) 2018-01-18
MX2019000526A (es) 2019-05-02
PE20190398A1 (es) 2019-03-13
US20190256582A1 (en) 2019-08-22
LT3484915T (lt) 2023-10-10
DK3484915T5 (da) 2024-09-02
KR102595764B1 (ko) 2023-10-30
DK3484915T3 (da) 2023-10-09
IL262710B1 (en) 2024-01-01
US20210363227A1 (en) 2021-11-25
DOP2021000026A (es) 2021-07-30
CA3024374A1 (en) 2018-01-18
JP7252888B2 (ja) 2023-04-05
PL3484915T3 (pl) 2024-03-25
FI3484915T3 (fi) 2023-11-15
CL2021002994A1 (es) 2022-09-09
ES2959883T3 (es) 2024-02-28
US20210355198A1 (en) 2021-11-18
US11117954B2 (en) 2021-09-14
CL2019000067A1 (es) 2019-07-26
CO2019001111A2 (es) 2019-08-20
WO2018010789A1 (en) 2018-01-18
UA126381C2 (uk) 2022-09-28
SI3484915T1 (sl) 2024-02-29
AU2017297757A1 (en) 2018-11-22
EP3484915A1 (en) 2019-05-22
KR20190027382A (ko) 2019-03-14
PH12018502348A1 (en) 2019-03-25
CN116199775A (zh) 2023-06-02
PH12018502348B1 (en) 2024-02-28
CR20190066A (es) 2019-09-10
AU2017297757B2 (en) 2024-06-13
ZA201807467B (en) 2024-04-24
ECSP19009170A (es) 2019-02-28
CN109563157B (zh) 2023-01-17
SG11201809879WA (en) 2018-12-28
EP4342911A1 (en) 2024-03-27
IL262710B2 (en) 2024-05-01
CN109563157A (zh) 2019-04-02
HUE063272T2 (hu) 2024-01-28
US11912757B2 (en) 2024-02-27
HRP20231196T1 (hr) 2024-01-19
JP2019533425A (ja) 2019-11-21
JP2023062036A (ja) 2023-05-02
MY190553A (en) 2022-04-27
IL262710A (en) 2018-12-31
EA201990243A1 (ru) 2019-07-31

Similar Documents

Publication Publication Date Title
DOP2021000026A (es) Anticuerpos que se unen específicamente a los epítopos del virus del zika y usos de los mismos
CL2024002250A1 (es) Uso de anticuerpo anti-vd1 para tratar cáncer, una enfermedad infecciosa o una enfermedad inflamatoria.
BR112017010298A2 (pt) anticorpos que neutralizam de modo potente vírus da raiva e outros lissavírus e usos dos mesmos
MX352338B (es) Anticuerpos neutralizantes del virus de la influenza a y usos de estos.
BR112018071276A2 (pt) anticorpos anti-il-33, composições, métodos e usos dos mesmos
JOP20200078A1 (ar) أجسام مضادة خاصة بـ cd47 وpd-l1
BR112018002406A2 (pt) anticorpos que neutralizam potentemente o vírus da hepatite b e usos dos mesmos
MX385673B (es) Productos terapeuticos de anticuerpos que se enlazan a cd47.
BR112018012352A2 (pt) anticorpos anti-lag3 e fragmentos de ligação ao antígeno
BR112018012344A2 (pt) anticorpos que se ligam especificamente a hla-dr e seus usos
CO2018012415A2 (es) Proteínas de unión específica y usos de las mismas
BR112018003326A2 (pt) anticorpos de ligação de linfopoietina estromal tímica (tslp) e métodos de uso dos anticorpos
BR112018006360A2 (pt) anticorpos agonísticos que se ligam especificamente ao cd40 humano e métodos de uso
JO3555B1 (ar) جسم مضاد يبطل فعالية فيروس الالتهاب الرئوي البشري
PH12020550025A1 (en) Multispecific antibodies specifically binding to zika virus epitopes and uses thereof
JOP20160131B1 (ar) الأجسام المضادة للعامل xi وطرق الاستخدام
AU2015347015A8 (en) Antibody drug conjugates
BR112016011401A2 (pt) moduladores de aplnr e utilizações dos mesmos
BR112014023063A2 (pt) anticorpos que neutralizam rsv, mpv e pvm e usos dos mesmos
MX2016002166A (es) Anticuerpos.
WO2016075546A3 (en) Antibodies that neutralize ebola virus and uses thereof
BR112016024742A2 (pt) método para a seleção de uma proteína, proteínas de ligação ao antígeno, anticorpos, imunoconjugado, formulação farmacêutica, uso do anticorpo, ácido nucleico e polipeptídeo
EA201992186A1 (ru) Антитела к par2 и пути их применения
BR112017003108A2 (pt) anticorpo ou fragmento de ligação a antígeno do mesmo, polipeptídeo isolado, ácido nucleico isolado, vetor de expressão, célula hospedeira, composição, métodos para produção de um anticorpo ou fragmento de ligação a antígeno, para tratamento de câncer e de uma infecção ou doença infecciosa, para detecção da presença de um peptídeo de tigit ou um fragmento do mesmo e para aumentar a atividade de uma célula imune e a atividade antitumoral de um anticorpo anti-tigit, vacina, e, uso de um anticorpo ou fragmento de ligação a antígeno
BR112017006203A2 (pt) anticorpos isolado, caninizado e monoclonal ou fragmento de ligação ao antígeno dos mesmos, ácido nucleico isolado, vetor de expressão, célula hospedeira, peptídeo antigênico isolado, proteína de fusão, composição farmacêutica, e, método de aumento da atividade de uma célula imune.

Legal Events

Date Code Title Description
B25G Requested change of headquarter approved

Owner name: HUMABS BIOMED SA (CH)

B350 Update of information on the portal [chapter 15.35 patent gazette]
B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]
B154 Notification of filing of divisional application [chapter 15.50 patent gazette]

Free format text: O PEDIDO FOI DIVIDIDO NO BR122024006890-7 PROTOCOLO 870240030675 EM 09/04/2024 11:28.

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 8A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2840 DE 10/06/2025.